Access icon

Case Report March 23, 2023

Quetiapine-Induced Neuroleptic Malignant Syndrome

; ; ; ; ;

Prim Care Companion CNS Disord 2023;25(2):22cr03332

  1. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870–876. PubMed CrossRef
  2. Tse L, Barr AM, Scarapicchia V, et al. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015;13(3):395–406. PubMed CrossRef
  3. Ware MR, Feller DB, Hall KL. Neuroleptic malignant syndrome: diagnosis and management. Prim Care Companion CNS Disord. 2018;20(1):17r02185. PubMed
  4. Detweiler MB, Sullivan K, Sharma TR, et al. Case reports of neuroleptic malignant syndrome in context of quetiapine use. Psychiatr Q. 2013;84(4):523–541. PubMed CrossRef
  5. Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72(9):1222–1228. PubMed CrossRef
  6. Sienaert P, van Harten P, Rhebergen D. The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia. Handb Clin Neurol. 2019;165:415–428. PubMed CrossRef
  7. Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D. 2015;15(1):45–62. PubMed CrossRef
  8. Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. Ann Pharmacother. 2016;50(11):973–981. PubMed CrossRef
  9. van Rensburg R, Decloedt EH. An approach to the pharmacotherapy of neuroleptic malignant syndrome. Psychopharmacol Bull. 2019;49(1):84–91. PubMed
  10. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185–202. PubMed CrossRef